Spero Therapeutics announced that it has received clearance by the U.S. Food and Drug Administration, FDA, for its investigational new drug, IND, application, to evaluate SPR206 in a Phase 2 clinical study. “Clearance of this IND is an important milestone in our SPR206 development program, as we prepare to advance this drug candidate into a Phase 2 trial in HABP/VABP,” said Kamal Hamed, Spero’s Chief Medical Officer. “HABP/VABP are serious infections associated with high mortality and substantial morbidity, and their management has been complicated by the increasing prevalence of difficult-to-treat and MDR Gram-negative pathogens. SPR206 is being developed to address this unmet need, and if approved, we believe it could provide clinicians with a valuable new therapeutic option.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on SPRO:
- Spero Therapeutics Announces Clearance of IND for SPR206 to Treat MDR Gram-negative Bacterial Infections
- Spero Therapeutics to Present at Cowen’s 44th Annual Healthcare Conference
- Spero Therapeutics Announces Chief Legal Officer’s Resignation
- Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Spero Therapeutics expects cash to fund requirements into late 2025